-
Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001
•
Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a Phase III clinical study for its investigational drug VSA001, which is being studied for the treatment of familial chylomicronemia syndrome (FCS) in China. A total of 36 FCS patients have been enrolled and will be…
-
CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
•
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy VSA001, Sperogenix Therapeutics’ vamorolone, and Zai Lab’s (HKG: 9688) efgartigimod are on track for breakthrough therapy designation (BTD) status awards in China. VSA001 for Familial Chylomicronemia Syndrome (FCS)VSA001 is designed to reduce triglyceride levels in…
